Ashford Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.51M | Hold |
9,078
| – | – | 0.48% | 50 |
|
|
2026
Q1 | $4.05M | Buy |
9,078
+833
| +10% | +$388K | 0.5% | 48 |
|
|
2025
Q4 | $3.74M | Hold |
8,245
| – | – | 0.42% | 55 |
|
|
2025
Q3 | $3.23M | Buy |
8,245
+538
| +7% | +$225K | 0.36% | 55 |
|
|
2025
Q2 | $3.43M | Sell |
7,707
-485
| -6% | -$224K | 0.4% | 49 |
|
|
2025
Q1 | $3.97M | Buy |
8,192
+273
| +3% | +$127K | 0.51% | 48 |
|
|
2024
Q4 | $3.19M | Hold |
7,919
| – | – | 0.38% | 51 |
|
|
2024
Q3 | $3.68M | Sell |
7,919
-481
| -6% | -$231K | 0.46% | 49 |
|
|
2024
Q2 | $3.94M | Hold |
8,400
| – | – | 0.53% | 51 |
|
|
2024
Q1 | $3.51M | Sell |
8,400
-956
| -10% | -$404K | 0.48% | 46 |
|
|
2023
Q4 | $3.81M | Buy |
9,356
+3,299
| +54% | +$1.22M | 0.51% | 46 |
|
|
2023
Q3 | $2.11M | Sell |
6,057
-420
| -6% | -$147K | 0.31% | 51 |
|
|
2023
Q2 | $2.28M | Sell |
6,477
-106
| -2% | -$35.7K | 0.32% | 46 |
|
|
2023
Q1 | $2.07M | Buy |
6,583
+7
| +0.1% | +$2.1K | 0.31% | 48 |
|
|
2022
Q4 | $1.9M | Sell |
6,576
-167
| -2% | -$50.9K | 0.29% | 49 |
|
|
2022
Q3 | $1.95M | Sell |
6,743
-2,462
| -27% | -$708K | 0.3% | 48 |
|
|
2022
Q2 | $2.59M | Sell |
9,205
-8
| -0.1% | -$2.14K | 0.37% | 49 |
|
|
2022
Q1 | $2.4M | Sell |
9,213
-544
| -6% | -$129K | 0.26% | 58 |
|
|
2021
Q4 | $2.14M | Buy |
9,757
+1,568
| +19% | +$305K | 0.21% | 62 |
|
|
2021
Q3 | $1.49M | Buy |
8,189
+1,183
| +17% | +$231K | 0.13% | 67 |
|
|
2021
Q2 | $1.41M | Sell |
7,006
-420
| -6% | -$87.9K | 0.13% | 70 |
|
|
2021
Q1 | $1.6M | Buy |
7,426
+1,717
| +30% | +$377K | 0.15% | 65 |
|
|
2020
Q4 | $1.35M | Buy |
5,709
+219
| +4% | +$50.2K | 0.13% | 67 |
|
|
2020
Q3 | $1.49M | Sell |
5,490
-361
| -6% | -$99.6K | 0.18% | 58 |
|
|
2020
Q2 | $1.7M | Buy |
5,851
+863
| +17% | +$234K | 0.22% | 55 |
|
|
2020
Q1 | $1.19M | Buy |
4,988
+228
| +5% | +$52.3K | 0.21% | 56 |
|
|
2019
Q4 | $1.04M | Buy |
4,760
+2
| +0% | +$405 | 0.14% | 61 |
|
|
2019
Q3 | $806K | Buy |
4,758
+961
| +25% | +$170K | 0.12% | 69 |
|
|
2019
Q2 | $696K | Hold |
3,797
| – | – | 0.09% | 74 |
|
|
2019
Q1 | $698K | Sell |
3,797
-383
| -9% | -$70.7K | 0.1% | 75 |
|
|
2018
Q4 | $693K | Hold |
4,180
| – | – | 0.11% | 75 |
|
|
2018
Q3 | $806K | Buy |
+4,180
| New | +$744K | 0.1% | 74 |
|
Other funds holding VRTX
Ashford Capital Management's VRTX Position: Q2 2026 in Review
Ashford Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 9,078 shares worth $4.51M. The position accounts for 0.48% of the portfolio, ranked #50.
Ashford Capital Management first reported a position in VRTX in Q3 2018 and has held it in 32 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Ashford Capital Management held 9,078 shares of Vertex Pharmaceuticals worth $4.51M as of Q2 2026.
- Ashford Capital Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
- Vertex Pharmaceuticals made up 0.48% of Ashford Capital Management's portfolio in Q2 2026, its #50 holding.
- Ashford Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Ashford Capital Management's 13F filing for Q2 2026, filed 21 Aug 2026.